140174-48-7

Usage

Uses

Used in Pharmaceutical Industry:
N,N-Dimethyl 4-formyl-1H-imidazole-1-sulfonamide is used as a key building block for the synthesis of various drugs, contributing to the development of new therapeutic agents.
Used in Antimicrobial Applications:
N,N-Dimethyl 4-formyl-1H-imidazole-1-sulfonamide is utilized for its antimicrobial properties, serving as a potential agent in the treatment of bacterial and fungal infections, thereby offering a new avenue for combating microbial diseases.
Used in Research as a Photochemical Probe:
N,N-Dimethyl 4-formyl-1H-imidazole-1-sulfonamide is employed as a photochemical probe for studying the structure and function of nucleic acids, aiding in the advancement of our understanding of these fundamental biomolecules.

Upstream product

• 3034-50-2 4⁽⁵⁾formylimidazole 
• 13360-57-1 dimethylamino sulfonyl chloride 
• 78162-58-0 N,N-dimethyl-1H-imidazole-1-sulfonamide 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1020818-05-6 5-[((3-[1,3]dioxolan-2-yl-2,4-difluoro-phenyl)-ethyl-amino)-methyl]-imidazole-1-sulfonic acid dimethylamide 
• 1020818-04-5 5-[(3-[1,3]dioxolan-2-yl-2,4-difluoro-phenylamino)-methyl]-imidazole-1-sulfonic acid dimethylamide 

Relevant academic research and scientific papers

TIMPZ: An Exquisite Building Block for Metal/Hydrogen Coordination Polymers

The novel polynitrogenated ligand tetra-[4(5)-imidazoyl]pyrazine (TIMPZ, 1) and its pincer complex of FeII are described. This ligand has an outstanding ability to aggregate in 1D-superstructures by means of hydrogen bonding or metal chelation. TIMPZ shows an unprecedented conformational control over the supramolecular assembly. Metal or hydrogen coordination switches the conformation of peripheral rings driving the assembly preferences. For [Fen(TIMPZ)n+1]2n+ complexes, UV/Vis spectroscopy shows a bathochromic shift of the main visible absorption band with higher “n” values. TIMPZ also has hydrogen-bond triggered excited-state intramolecular proton transfer (ESIPT) fluorescence, which is completely inhibited by chelation with transition metals.

A Photoswitchable Agonist for the Histamine H3 Receptor, a Prototypic Family A G-Protein-Coupled Receptor

Spatiotemporal control over biochemical signaling processes involving G protein-coupled receptors (GPCRs) is highly desired for dissecting their complex intracellular signaling. We developed sixteen photoswitchable ligands for the human histamine H3 receptor (hH3R). Upon illumination, key compound 65 decreases its affinity for the hH3R by 8.5-fold and its potency in hH3R-mediated Gi protein activation by over 20-fold, with the trans and cis isomer both acting as full agonist. In real-time two-electrode voltage clamp experiments in Xenopus oocytes, 65 shows rapid light-induced modulation of hH3R activity. Ligand 65 shows good binding selectivity amongst the histamine receptor subfamily and has good photolytic stability. In all, 65 (VUF15000) is the first photoswitchable GPCR agonist confirmed to be modulated through its affinity and potency upon photoswitching while maintaining its intrinsic activity, rendering it a new chemical biology tool for spatiotemporal control of GPCR activation.

Studies toward the total synthesis of nagelamide K

A stereocontrolled strategy toward the synthesis of nagelamide K has been developed. The dimeric imidazole acrylate, diimidazolidenesuccinate, was constructed as a synthetic precursor by a Ni-catalyzed coupling reaction; the microwave-promoted intramolecular aza-Michael addition afforded the imidazo[1,5-a]pyridine core structure of nagelamide K in high stereoselectivity. A detaurine-dediamino analogue of nagelamide K has been prepared.

OXO-SUBSTITUTED COMPOUND

Provided is a novel compound that has an excellent β-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent β-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a β-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and β-lactam drugs.

Functionalization of the Imidazole Backbone by Means of a Tailored and Optimized Oxidative Heck Cross-Coupling

A general and selective Pd-catalyzed cross-coupling of aromatic boronic acids with vinyl-imidazoles is disclosed. Unlike most cross-coupling reactions, this method operates well in absence of bases avoiding the formation of by-products. The reactivity is highly enhanced by the presence of nitrogen-based ligands, in particular bathocuproine. The method involves MnO2 as oxidant for the oxidation Pd (0)→Pd (II), a much weaker oxidant than previously reported in the literature. This allows for the use of reactants that possess a multitude of functional groups. A scope and limitation study involving a series of 24 boronic acids, whereof 18 afforded TMs in yields in the range 41–95%. The disclosed method constitutes the first general method for the oxidative Heck cross-coupling on the imidazole scaffold, which moreover operates with a selection of other heterocycles. (Figure presented.).

Design of coordination interaction of Zn(II) complex with oligo-aspartate peptide to afford a high-affinity tag-probe pair

A complementary recognition pair consisting of a genetically encodable peptide tag and a small molecular probe isa powerful tool to specifically label and manipulate a protein ofinterest under biological conditions. In this study, we report the redesign of a tag-probe pair comprising an oligo-aspartate peptide tag (such as DDDD) and a binuclear zinc complex. Isothermal-titration calorimetry screening of binding between the series of peptides and zinc complexes revealed that the binding affinity was largely influenced by subtle changes of the ligand structure of the probe. However, the binding was tolerant to differences of the tag peptide sequence. Of those tested, a pair containing a peptide tag (DDAADD) and a binuclear zinc complex possessing 4-chloropyridines (3-2Zn(II)) showed the strongest binding affinity (Ka = 3.88 × 105 M-1), which was about 10-fold larger than the conventional pair of D4-peptide tag (DDDD) and 1-2Zn(II) containing nonsubstituted pyridines (Ka = 3.73 × 104 M-1). The strong binding of this new complementary recognition pair enabled the rapid covalent labeling of a tag-fused maltose binding protein with a fluorescent zinc complex, demonstrating its potential utility in protein analysis.

Optimisation of imidazole compounds as selective TAAR1 agonists: Discovery of RO5073012

A series of imidazole compounds has been identified which affords potent and selective partial and full agonists of the TAAR1 receptor. Starting from 2-benzyl-imidazoline screening hits, a series of structurally related 2-benzyl- and 4-benzyl-imidazoles was investigated first, but it proved highly challenging to obtain compounds having sufficient selectivity against the adrenergic alpha 2 receptor. This issue could be successfully addressed by modification of the linker region and SAR exploration led to the discovery of highly selective isopropyl-substituted 4-aminomethyl-imidazole compounds. The work culminated in the identification of the selective TAAR1 partial agonist RO5073012 (4-chlorophenyl)-(1H-imidazol-4-ylmethyl)-isopropyl-amine, 24), which has a good pharmacokinetic profile after oral administration in rodents. RO5073012 has been found to be active in a behavioural rat model which is considered indicative for schizophrenia.

5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)

The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8- ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebrovascular amyloid angiopathy, multi- infarct dementia, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES

The present invention provides an advantageous production method of an imidazole derivative, which is suitable for industrial production. Compound (VI) is produced by reacting compound (I) with a Grignard reagent or a magnesium reagent, and a lithium reagent, and then reacting the resulting compound with compound (V).

Synthesis of 1-(Dimethylsulfamoyl)-2- and 5-Imidazolecarboxaldehydes. Rearrangement of 1-(Dimethylsulfamoyl)-5-imidazolecarboxaldehyde to the 4-Carboxaldehyde

Lithiation of 1-(dimethylsulfamoyl)imidazole by n-butyllithium, followed by substitution with dimethylformamide provided 1-(dimethylsulfamoyl)-2-imidazolecarboxaldehyde in 19percent yield.When 1-(dimethylsulfamoyl)-2-(tert-butyldimethylsilyl)imidazole was lithiated by sec-butyllithium, followed by methyl formate, there was obtained 1-(dimethylsulfamoyl)-2-(tert-butyldimethylsilyl)-5-imidazolecarboxaldehyde (57percent).Removal of the silyl group by acetic acid yielded 1-(dimethylsulfamoyl)-5-imidazolecarboxaldehyde (11, 96percent) as a gum.Isomerization of 11 took place slowly at room temperature (10 days), or faster in tetrahydrofuran solution containing triethylamine (2 hours) to form crystalline 1-(dimethylsulfamoyl)-4-imidazolecarboxaldehyde (12) in 68percent yield.Proton and carbon-13 nmr spectra were alanyzed to determine the structure of the isomers.However, only X-ray crystallography established the structure of 1-(dimethylsulfamoyl)-4-imidazolecarboxaldehyde, unequivocally.A mechanism for the isomerization of 11 to 12 is proposed.